Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial by Ze Zhang, Wenwen Zhang, Mingyi Chen, Hongguang Wang, Tao Wan, Bingyang Hu, Shichun Lu, Zhanbo Wang, Xiaochen Zhao, Yuezong Bai, Yafei Wang, Xuerui Li, Shiqing Chen, Feilong Zhao, Jinping Cai, Shuang Tong, Haowen Tang, Tianyu Jiao, Junfeng Li, Huiyi Ye, Fangzhou Wang, Junning Cao, Lantian Tian, Shouwang Cai, Minggen Hu

Get full text